With the emergence of the new ed drug, the tempting pharmaceutical giants are not only Lilly. The giants have their own flexible news channels, including Pfizer, a big company. It’s a coincidence that Pfizer and Lilly are mortal enemies in ed drugs and fight every year!

Pfizer’s Viagra patent expires this year, and countless generic drug companies will seize their interests by then. There is also the strong rival of Eli Lilly! Their competitive product "Cialis", which successfully defeated Viagra with sales last year (2013)!

Viagra is already difficult to resist its opponents. Cialis is better than Viagra in terms of duration and side effects. If they are allowed to seize this new technology, Pfizer, a drug that can bring considerable benefits to the company every year, can be delisted.

This is why Ian Reed frowned today.

On his desk was a newly obtained investigation report, which stated that this code-named ed drug has a longer and more effective ability and has almost no side effects. Moreover, it can also give people the effect of prolonging the time of committing crimes!

These two effects combined can be called "upgraded versions". They should be the next generation of biotechnology, but they were developed by Chinese pharmaceutical companies that have always been able to use generic drugs and copycats. And the time is still so short that two phases of clinical practice were quickly carried out?

"Is this our efficiency?" Reed was angry at the men in front of him.

The R&D department and other senior executives' faces were not very good-looking, but no one dared to defend themselves when the boss was angry. After all, in the past two years, Pfizer's performance has indeed been average. First, Johnson & Johnson and Novartis robbed him of the first place, but now Cheng Yaojin is out halfway!

The main pressure comes from the board of directors. Those people only look at profits, but without profits, everything is bullshit! Pfizer is currently facing the trouble of "escape from the United States", which also requires funds and a rising stock market to realize mergers and acquisitions and transfer overseas.

Reed knew very well that the company urgently needed good grades - and good grades needed new drugs. This new drug is currently in the hands of companies that do not know the foundation, and there is no need to think about it. Other rivals will definitely find ways to contact and grab the fruits.

"What are you suggesting now?" Reed finally realized that venting his anger on his subordinates would not solve the problem.

The subordinates breathed a sigh of relief, and someone spoke: "Our focus is to get this new drug, and we cannot be taken first by Eli Lilly or other opponents."

"Speak on," Reed said.

"Our company in China has received news that the investor of that pharmaceutical company is currently in the United States and is a high-tech battery business. He also invests in pharmaceutical companies in California. We can send people to California to contact him."

"As far more detailed information about him and the new drug, the efficacy and other information, please get it for me." Reed said, thinking of its amazing effect, and then added: "No matter how much!"

...

On the other hand, Eli Lilly is also concerned.

Although they are not as large as Pfizer, their ambitions are not small. In recent years, they have just tasted the sweetness of "Cialis" and are trampling their opponents under their feet. How can they see the rise of another new drug? Doesn't this mean that their research and development and funding over the years have been wasted?

They contacted and mastered the information of Fuguo Pharmaceutical earlier than Pfizer, and learned that this is a poor pharmaceutical company with financial strength...weakness. I don’t know how it can withstand the consumption of new drug research and development? Unless there is a genius. But no matter what, the new drug is strong and remains unchanged.

Mastering this new drug not only means that it can not only sweep Pfizer's rival, Ko, but also sweep the market of patented drugs, become the overlord, and more than double its sales. What is this achievement?

If they miss it, they will not only not be able to eat this market, but may also throw away all the things they have and feed the cake to their opponents!

So the company boss also issued an order: "Fight for this new drug with all your might!"

...

The disruption of cheating new drugs has brought trouble and opportunities to the giants.

Meng Qian soon received a reply from Eli Lilly. They were willing to interview in person, which was very sincere - it also proved that his offer was not too difficult?

Following the gift, Pfizer also took the initiative to contact his assistant, saying that he was very interested in the new drug and was willing to send someone to interview in person.

Meng Qian is not stupid. When he saw that there were two giants interested, he realized that there was room for operation.

It also indirectly proves that the $5 billion he shouted casually in front of him may not be too high... He took the time to talk to his assistant and analyzed the market in this regard.

Ralph then went to investigate and get information and contacted Onix Pharmaceuticals - the benefits of being a shareholder will be represented by someone on his board of directors.

Then Meng Qian got the result: "Is my offer low?"

According to the information, Ralph said: "If you really follow your determination to win the new drug market, this price may be slightly lower."

"However, pharmaceutical companies that purchase technology will also bear the cost of the failure of the third phase and the failure of the application. The evaluation of the selling price is mainly based on the level of the core technology."

"That's low." Meng Qian was confident in his plug-in.

After thinking about it, he felt that this was the reason. He spent 3 billion US dollars (in dream) to develop it and obtained a new drug that could seize the market of hundreds of billions for 20 years, and only sold it for $5 billion?

It’s a loss, it’s really a loss! Meng Qian is very shameless in business. Although he has called out 5 billion, and changing his words is suspected of slapping himself in the face, it does not mean that there are no additional conditions.

So when he met Eli Lilly, he offered a price: "Five billion US dollars of funds, plus 5% of drug sales in twenty years."

The other party's expression changed, obviously scaring the subsequent additions.

Don’t underestimate the 5% share of this sales. Maybe it has the same effect as a joint venture with a 50% share!

For example, if the drug sales are 10 billion, the share of 5% is 500 million; if the holding of 50% is 10%, the dividend will also be 500 million!

This is like a lion's mouth!

"We can still discuss it." The other party just said he was dissatisfied. Although he knew they could still make money, who would want to make less money?

"You guys keep in touch with my assistant." Meng Qian said with a smile. He is a little busy now and has no time to bargain - he needs a professional negotiating team.

Similarly, during a brief contact with Pfizer the next day, Meng Qian also offered similar conditions. The other party was interested in a one-time buyout, but the sales revenue was not enough.

"The conditions are beyond our ability to bear, and your company has not allowed new drugs to undergo large-scale clinical practice. We are taking great risks..."

"I understand." Meng Qian nodded, "You need the third issue of data, and then I will open a more realistic price code, right?"

The other party affirmed: "Considering the actual situation of your company, we are willing to take this part of the risk, but we just hope that the overall price will be more realistic."

In the absence of more clinical results, Meng Qian's asking price is exaggerated.

Five billion will inevitably drop to two billion, and sales share cannot be achieved - this is what the giants think.

But for Meng Qian, he might as well not sell this result. He has survived this difficult period of funding development. After the drug is launched in the future, it will at least bring him more than 20 billion yuan in profits within 20 years.

So his interest temporarily shifted, and he handed over these professional negotiations to experts.

If the price is right, he will sell it, and if it is not right, keep it.

This kind of major business negotiation takes a long time just to argue. As the boss of many companies, Meng Qian did not have the time to slap his mouth.
Chapter completed!